Enzastaurin
- Generic Name
- Enzastaurin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H29N5O2
- CAS Number
- 170364-57-5
- Unique Ingredient Identifier
- UC96G28EQF
- Background
Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.
- Indication
Investigated for use/treatment in brain cancer, lymphoma (non-hodgkin's), and lung cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 86
- Registration Number
- NCT00437294
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durban, South Africa
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT00437268
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubbock, Texas, United States
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 73
- Registration Number
- NCT00428714
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT00420381
- Locations
- 🇺🇸
Gynecologic Oncology Group 215-854-0770, Philadelphia, Pennsylvania, United States
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 109
- Registration Number
- NCT00415363
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umea, Sweden
A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT00414960
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT00402116
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Francisco, California, United States
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")
- Conditions
- Interventions
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 153
- Registration Number
- NCT00391118
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 758
- Registration Number
- NCT00332202
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
An Open Label Study of Oral Enzastaurin in Participants With Cancer
- First Posted Date
- 2006-03-31
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT00309140
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sun City, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.